Phase III clinical trial - Appareil pulmonaire
CodeBreak202
Appareil pulmonaire
Essai clinique fermé
Public cible
Adulte
A Phase 3, Multicenter, Randomized, Open-label;Study Evaluating Efficacy of Sotorasib Platinum;Doublet Combination Versus Pembrolizumab;Platinum Doublet Combination as a Front-Line;Therapy in Subjects With Stage IV or Advanced;Stage IIIB/C Nonsquamous NonÀSmall Cell Lung;Cancers, Negative for PD-L1, and Positive for;KRAS p.G12C (CodeBreaK 202)
Description de l'essai
To compare progression-free survival;(PFS) in subjects who receive;sotorasib with platinum doublet;chemotherapy versus subjects who;receive pembrolizumab with platinum;doublet chemotherapy.
Liens utiles
NICOLAS GIRARD
Investigateur principal